시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 천식 및 만성 폐쇄성 폐질환(COPD) 치료제 시장 보고서(2025년)
Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Global Market Report 2025
상품코드 : 1764252
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,292,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,095,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,897,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

천식 및 만성 폐쇄성 폐질환(COPD) 치료제 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 9.4%로 성장할 전망이며, 509억 9,000만 달러로 성장이 예측됩니다. 이러한 성장이 전망되는 배경에는, 맞춤형 치료에 대한 지향 고조, 생물 제제 및 차세대 치료의 사용 확대, 환경 알레르기 환자 급증, 임상 검사 및 규제 당국에 의한 승인 확대, 만성 비감염성 질환의 유병률 증가 등이 있습니다. 예측 기간 중에 예측되는 주목할 만한 동향으로는 스마트 흡입기 기술의 출현, 이중작용 기관지 확대약의 개발, 전자 진료기록카드(EHR) 및 약제 데이터의 통합, 생물 약제 혁신의 진전, 약제 개발 프로세스에서 기계 학습의 용도 등이 있습니다.

천식 및 만성 폐색성 폐 질환(COPD) 치료제 시장의 주요 기업은 Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd. (Roche), Merck & Co. Inc., Sanofi, AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc (GSK), Eli Lilly and Company, Amgen, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Astellas Pharma, AptarGroup, Chiesi Farmaceutici S.p.A., Dr. Reddy's Laboratories, Cipla Inc., Lupin Limited, Zydus Cadila, Glenmark Pharmaceuticals, Vectura Group 및 Aurobindo Pharma입니다.

2024년 천식 및 만성 폐쇄성 폐질환(COPD) 치료제 시장에서는 북미가 최대 지역이었습니다. 아시아태평양은 예측 기간 중 가장 급성장하는 지역으로 예상됩니다. 천식 및 만성 폐쇄성 폐질환(COPD) 치료제 리포트 대상 지역은, 아시아 태평양, 서유럽, 중동유럽, 북미, 남미, 중동 및 아프리카입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Asthma and chronic obstructive pulmonary disease (COPD) medications are utilized to control and treat respiratory disorders that lead to breathing difficulties. These medications function by alleviating inflammation, relaxing the muscles in the airways, and enhancing airflow to the lungs, which helps relieve symptoms like shortness of breath, coughing, and wheezing. They are most commonly delivered through inhalers or nebulizers to ensure effective administration directly to the lungs.

The primary categories of drugs used for treating asthma and COPD include bronchodilators, corticosteroids, combination therapies, and leukotriene modifiers. Bronchodilators act rapidly to relax airway muscles, thereby opening the airways and offering quick relief from symptoms associated with asthma and COPD. These medications are administered through multiple methods, such as inhalation, oral tablets, injections, nasal sprays, and others. They are prescribed for a range of patient populations including adults, children, and the elderly, and are employed in treating various conditions such as asthma, COPD, allergic rhinitis, and pulmonary hypertension. The distribution of these medications occurs via multiple channels, including hospital pharmacies, retail outlets, online platforms, and drugstores.

The asthma and COPD drugs market research report is one of a series of new reports from The Business Research Company that provides asthma and COPD drugs market statistics, including the asthma and COPD drugs industry global market size, regional shares, competitors with the asthma and COPD drugs market share, detailed asthma and COPD drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the asthma and COPD drugs industry. This asthma and COPD drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The asthma and COPD drugs market size has grown strongly in recent years. It will grow from $32.52 billion in 2024 to $35.66 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. This growth during the historical period is primarily attributed to increasing levels of air pollution, a rise in smoking habits, heightened awareness of respiratory illnesses, growing usage of corticosteroids and bronchodilators, and an increase in healthcare spending.

The asthma and COPD drugs market size is expected to see strong growth in the next few years. It will grow to $50.99 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. This anticipated growth is driven by the rising preference for personalized treatment approaches, the growing use of biologics and next-generation therapies, a surge in environmental allergy cases, expansion in clinical trials and regulatory approvals, and the increasing prevalence of chronic non-communicable diseases. Notable trends projected during the forecast period include the emergence of smart inhaler technologies, development of dual-action bronchodilators, integration of drug data with electronic health records (EHRs), advancements in biopharmaceutical innovations, and the application of machine learning in the drug development process.

Major players in the asthma and COPD drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd. (Roche), Merck & Co. Inc., Sanofi, AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc (GSK), Eli Lilly and Company, Amgen, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Astellas Pharma, AptarGroup, Chiesi Farmaceutici S.p.A., Dr. Reddy's Laboratories, Cipla Inc., Lupin Limited, Zydus Cadila, Glenmark Pharmaceuticals, Vectura Group, and Aurobindo Pharma.

North America was the largest region in the asthma and COPD drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in asthma and COPD drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the asthma and COPD drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The asthma and COPD drugs market consists of sales of bronchodilators, inhaled corticosteroids, combination inhalers, leukotriene modifiers, biologics, theophylline, and systemic corticosteroids. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on asthma and chronic obstructive pulmonary disease (copd) drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for asthma and chronic obstructive pulmonary disease (copd) drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The asthma and chronic obstructive pulmonary disease (copd) drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Subsegments

Table of Contents

1. Executive Summary

2. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Characteristics

3. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Trends And Strategies

4. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Growth Analysis And Strategic Analysis Framework

6. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Segmentation

7. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Regional And Country Analysis

8. Asia-Pacific Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

9. China Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

10. India Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

11. Japan Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

12. Australia Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

13. Indonesia Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

14. South Korea Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

15. Western Europe Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

16. UK Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

17. Germany Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

18. France Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

19. Italy Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

20. Spain Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

21. Eastern Europe Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

22. Russia Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

23. North America Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

24. USA Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

25. Canada Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

26. South America Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

27. Brazil Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

28. Middle East Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

29. Africa Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

30. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Competitive Landscape And Company Profiles

31. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Other Major And Innovative Companies

32. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

34. Recent Developments In The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

35. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기